Results of a study examining the impact of Corona Virus / Covid 19 on rheumatology patients on immunosuppressive therapies has just been published.
The study assessed the outcomes of 600 rheumatology patients who developed Corona Virus infections and is the biggest duty of its kind – and the results are promising.
The results are relevant to patients suffering from inflammatory arthritis (eg rheumatoid, ankylosing spondylitis, psoriatic arthritis), SLE, Vasculitis where they are on immunosuppressive treatments
Risk factors for hospitalisation for patients with rheumatic diseases very similar to those in the general population eg older patients (>65yrs), those with heart conditions (including high blood pressure), lung conditions, diabetes or chronic kidney failure.
Taking conventional DMARD therapies was not associated with an increased risk of hospital admission in those who developed Corona Virus infection.
Taking Biologic DMARD therapies was not associated with and increased risk of hospital admission in those who developed Corona Virus infection.
Taking steroids increased the risk of hospitalisation in doses of Prednisolone (Deltacortil / prednisone) of 10mg per day or higher.
Please watch the accompanying series of videos for more information.